AstraZeneca Announces First Presentation Of Pivotal SEROQUEL XR TM Bipolar Studies
New pivotal trial data from two clinical studies with SEROQUEL XR™ (quetiapine fumarate) once daily Extended Release Tablets were presented today at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark..
Supplemental New Drug Application For RISPERDAL R CONSTA R Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder
Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL CONSTA [(risperidone) Long-Acting Injection] to the U.
ABILIFY R aripiprazole Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar Disorder And Schizophrenia
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of Schizophrenia in adolescents (aged 13-17).
Problems Identified With Diagnosis Of Bipolar Disorder
A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).
Benefits Of Omega 3s Still Unclear For Bipolar Disorder
Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies.
Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia.
* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol.
Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting
Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # 44 and # 80).
Astrazeneca Submits Supplemental New Drug Applications For Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression
AstraZeneca announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
Most Psychiatric Patients Have More Than 1 Diagnosis, Study Finds
A new study by Rhode Island Hospital researchers reports that the majority of 2, 300 psychiatry outpatients had more than one disorder when seeking treatment, and more than one-third had at least three disorders. The study is published in the February 2008 edition of the journal Psychological Medicine.
New Report Dispels Greatest Myths About Bipolar Disorder
New free report reveals that many individuals misunderstand bipolar disorder and have bought into "bipolar lies." David Oliver, founder of Bipolar Central, has recently released a free report that uncovers and dispels various widely circulated myths about bipolar disorder.